SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-007713
Filing Date
2024-05-10
Accepted
2024-05-10 10:30:38
Documents
52
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q viri-20240331x10q.htm   iXBRL 10-Q 628957
2 EX-31.1 viri-20240331xex31d1.htm EX-31.1 12316
3 EX-31.2 viri-20240331xex31d2.htm EX-31.2 12207
4 EX-32.1 viri-20240331xex32d1.htm EX-32.1 6886
5 EX-32.2 viri-20240331xex32d2.htm EX-32.2 6902
  Complete submission text file 0001558370-24-007713.txt   3230131

Data Files

Seq Description Document Type Size
6 EX-101.SCH viri-20240331.xsd EX-101.SCH 27211
7 EX-101.CAL viri-20240331_cal.xml EX-101.CAL 23235
8 EX-101.DEF viri-20240331_def.xml EX-101.DEF 111921
9 EX-101.LAB viri-20240331_lab.xml EX-101.LAB 250227
10 EX-101.PRE viri-20240331_pre.xml EX-101.PRE 199073
56 EXTRACTED XBRL INSTANCE DOCUMENT viri-20240331x10q_htm.xml XML 350739
Mailing Address 44 MILTON AVENUE ALPHARETTA GA 30009
Business Address 44 MILTON AVENUE ALPHARETTA GA 30009 8666208655
Virios Therapeutics, Inc. (Filer) CIK: 0001818844 (see all company filings)

IRS No.: 854314201 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39811 | Film No.: 24933286
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)